Bio-Techne Showcases RNAscope Advances in Biomarker Detection at the 2025 USCAP Annual Meeting

Introduction

Bio-Techne Corporation, listed on NASDAQ under the ticker symbol TECH, is set to present its latest advancements in biomarker detection at the upcoming USCAP Annual Meeting. Scheduled for March 22-27, 2025, in Boston, MA, this event will mark a significant milestone for the company as it introduces innovative solutions designed to improve pathology laboratory workflows and address critical gaps in biomarker detection. Among the highlights is the RNAscope technology developed by Advanced Cell Diagnostics (ACD), a Bio-Techne subsidiary.

RNAscope Technology Explained

RNAscope is a groundbreaking method that enhances the ability of pathologists to identify clinically relevant biomarkers. The technology utilizes a unique in-situ hybridization technique that allows for the detection of RNA in tissue samples. This enables researchers to observe and analyze the expression of specific genes within their native environment, providing crucial insights into disease mechanisms and potential treatments.

During the seminar, several leading pathologists will illustrate how they have successfully employed RNAscope technology in their practices. For instance, Dr. Rohit Mehra from the University of Michigan will present findings on TRIM63 mRNA as a surrogate marker in renal cell carcinoma. This represents a significant shift from traditional DNA FISH techniques, showcasing the advancements offered by RNAscope into the realm of pathology.

Expert Insights

The conference will feature a session entitled "RNAscope Lightning Lunch and Learn," where invited pathologists will share their experiences and findings. Dr. Vikram Deshpande from Beth Israel Deaconess Medical Center will discuss how albumin mRNA serves as a more efficient marker compared to secreted proteins in liver tumor cases. Furthermore, Dr. Brooke Howitt from Stanford University will touch upon the in situ detection of point mutations in gynecological tumors, illustrating RNAscope's capability to adapt to various molecular challenges. Lastly, Dr. Gregory Bean, also from Stanford, will present his findings on the direct detection of mRNA in specific translocations, reinforcing the versatility of the RNAscope platform in identifying complex carcinomas and improving diagnostic accuracy.

Revolutionizing Pathology Labs

According to Dr. Matt McManus, the President of Bio-Techne's Diagnostics and Spatial Biology Segment, these advancements signify a leap in in situ hybridization methods that enhance potential applications within pathology laboratories. The session at USCAP exemplifies the forefront of clinical and translational research, underlining the crucial role that cutting-edge technologies play in accurately detecting the molecular characteristics of diseases.

As the field of pathology continues to evolve, embracing innovative technologies like RNAscope is essential for clinicians aiming to improve diagnosis and treatment outcomes for patients. Bio-Techne's commitment to furthering scientific progress in this domain sets a precedent for what future pathology could look like - more precise, efficient, and patient-centered.

Conclusion

Bio-Techne's presentations at the 2025 USCAP Annual Meeting provide a valuable glimpse into the future of pathology. By leveraging the capabilities of RNAscope technology, the company aims to bridge the gaps in biomarker detection and enhance the capabilities of pathology laboratories. As more pathologists adopt these advanced solutions, patient care and outcomes are poised to improve significantly, showcasing the potential of translational discoveries in medicine.

For further insights into Bio-Techne and its pioneering work in the biomarker detection landscape, follow their journey on their official website and social media platforms.

Note: RNAscope technology is currently for research use only and is not intended for diagnostic procedures.